By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Catalent Pharma Solutions 

14 Schoolhouse Road

Somerset  New Jersey  08873  U.S.A.
Phone: 732-537-6200 Fax: n/a


About Catalent Biologics:

Catalent Biologics is a fast growing business within Catalent Pharma Solutions focused on providing innovative technologies and solutions to help more and better biologic treatments get to patients. The business includes our proprietary GPEx cell line engineering platform, our new state-of-the-art biomanufacturing facility in Madison, WI., and our market leading biologics analytical services in Kansas City and Research Triangle Park, NC. With the recent acquisition of Redwood Bioscience in Emeryville, CA, we have added the SMARTag Antibody Drug Conjugate technology, providing a next-generation ADC platform to our biologics customers. Leveraging our growing differentiated technology portfolio, world class manufacturing capability, and other integrated services across the Catalent network, Catalent Biologics is positioned to drive significant growth for Catalent.

Working for Catalent Biologics is an opportunity to join an entrepreneurial team that is building a new business. Catalent is aggressively growing in biologics, and is making significant investments in people and capabilities in this area. This is a unique opportunity to join a small, fast growing business, backed by a global public company. People joining our team will also have significant career development/progression opportunities as our business continues to grow and expand.

Key Statistics

Ownership: Public

Web Site: Catalent
Symbol: CTLT

Company News
NEMUS Bioscience And Catalent (CTLT) To Advance NB1222 Into Human Dosage Formulation Development 3/3/2017 6:27:37 AM
Catalent (CTLT) Completes Accucaps Acquisition To Expand Softgel Development And Manufacturing Capabilities And Capacity 2/16/2017 6:24:27 AM
Catalent (CTLT) Reports Second Quarter Fiscal Year 2017 Results 2/7/2017 6:36:22 AM
Catalent (CTLT) Release: Company Announces Second Quarter Fiscal Year 2017 Earnings Conference Webcast 1/19/2017 8:03:37 AM
Catalent (CTLT) To Develop Softgel Capsules For Jupiter Orphan Therapeutics’s Leading Orphan Disease Candidates 1/9/2017 11:45:34 AM
Catalent (CTLT) Completes Repricing Of Credit Agreement 12/12/2016 10:17:31 AM
Catalent (CTLT) Announces Launch Of Private Offering Of $400 Million (U.S. Dollar Equivalent) Of Euro-Denominated Senior Unsecured Notes Due 2024 11/28/2016 8:13:24 AM
Catalent (CTLT) Reports First Quarter Fiscal Year 2017 Results 11/8/2016 10:38:57 AM
Catalent (CTLT) Appoints Uwe Röhrhoff To Its Board Of Directors 11/1/2016 11:40:09 AM
Catalent (CTLT)'s $34 Million Expansion to Create 100 New Jobs in Wisconsin 10/24/2016 6:39:58 AM